Identification of a four-microRNA panel in serum as promising biomarker for colorectal carcinoma detection

Biomark Med. 2020 Jun;14(9):749-760. doi: 10.2217/bmm-2019-0605. Epub 2020 Jul 16.

Abstract

Background: Screening for colorectal carcinoma (CRC) lacks an efficient, inexpensive and noninvasive approach. The stable presence of serum miRNA is expected to become a new diagnostic marker. Materials & methods: Based on 135 CRC patients and 135 normal controls, this study was conducted in three phases to identify suitable serum miRNA for CRC diagnosis by using quantitative reverse transcription PCR. Bioinformatic assays were used for target genes prediction and functional annotation. Results: Serum expression level of seven miRNAs were significantly different between CRC patients and the normal controls. The final diagnostic panel (area under the curve = 0.893; sensitivity = 81.25%, specificity = 73.33%) consists of miR-203a-3p, miR-145-5p, miR-375-3p and miR-200c-3p. Conclusion: The four-miRNA panel may serve as a novel, noninvasive biomarker for CRC diagnosis and screening.

Keywords: biomarker; colorectal cancer; miR-145-5p; miR-200c-3p; miR-203a-3p; miR-375-3p; microRNA.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Biomarkers, Tumor / blood*
  • Case-Control Studies
  • Colorectal Neoplasms / blood*
  • Colorectal Neoplasms / diagnosis*
  • Colorectal Neoplasms / genetics
  • Female
  • Gene Expression Regulation, Neoplastic
  • Humans
  • Male
  • MicroRNAs / blood*
  • Middle Aged
  • ROC Curve

Substances

  • Biomarkers, Tumor
  • MicroRNAs